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Introduction: Because of its genetic underpinnings and consistent age of onset within families, autosomal dominant
Alzheimer’s disease (ADAD) provides a unique opportunity to conduct clinical trials of investigational agents as
preventative or symptom-delaying treatments. The design of such trials may be complicated by low rates of genetic
testing and disclosure among persons at risk of inheriting disease-causing mutations.
Methods: To better understand the attitudes toward genetic testing and clinical trials of persons at risk for ADAD, we
surveyed participants in the Dominantly Inherited Alzheimer’s Network (DIAN), a multisite longitudinal study of clinical
and biomarker outcomes in ADAD that does not require learning genetic status to participate.
Results: Eighty participants completed a brief anonymous survey by mail or on-line; 40 % reported knowing if they
carried a gene mutation, 15 % did not know but expressed a desire to learn their genetic status, and 45 % did not know
and did not desire to know their genetic status. Among participants who knew or wished to know their genetic status,
86 % were interested in participating in a clinical trial. Seventy-two percent of participants who did not wish to learn
their genetic status reported that they would change their mind, if learning that they carried a mutation gave
them the opportunity to participate in a clinical trial. Nearly all participants responded that they would be interested if
an open-label extension were offered.
Conclusions: These results suggest that the availability of clinical trials to prevent ADAD can affect persons’ desire to
undergo genetic testing and that consideration can be given to performing studies in which such testing is required.Introduction
Biomarker and clinicopathological studies suggest that
the pathophysiological process of Alzheimer’s disease (AD)
begins long before the onset of cognitive and functional
impairment [1–4]. Intervention early in this process may
be necessary to successfully alter the underlying biology
and clinical progression of disease [5, 6]. Clinical trials of
promising preventative therapies, however, require several-
year studies of hundreds to thousands of participants to be
adequately powered to detect a drug effect [7–9].* Correspondence: jgrill@uci.edu; batemanr@wustl.edu
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creativecommons.org/publicdomain/zero/1.0/Performance of prevention clinical trials in autosomal
dominant Alzheimer’s disease (ADAD) avoids some of
the challenges associated with sporadic disease. ADAD
is characterized by early age of onset (typically in the
fourth, fifth, or sixth decade of life) [10] and is also re-
ferred to as familial AD. ADAD is caused by mutations
in the presenilin (PSEN1 and PSEN2), and amyloid pre-
cursor protein (APP) genes [11], for which genetic test-
ing is available. Penetrance is near 100 % and the age of
symptom onset is largely consistent within families and
mutations [12–14]. Mutation carriers demonstrate bio-
chemical and neuroimaging changes that can precede
dementia by 15 years or more and may be used to iden-
tify windows of time relative to specific pathophysiologic
events in disease [4, 15]. ADAD thus presents a unique
opportunity to examine experimental preventative ther-
apies for AD: patients can be identified for whom thele distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
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therapy can be initiated at predictable times in relation
to measurable disease biomarkers. Moreover, in light
of the diagnostic reliability and consequent population
homogeneity, such studies require fewer patient partici-
pants and shorter total study lengths relative to trials in
sporadic AD [16, 17].
Despite these strengths, few clinical trials have been
performed in ADAD. One challenge to such studies is
selecting an appropriate design. An efficient study might
enroll only mutation carriers, randomize them to drug or
placebo (at a 1:1 ratio), and measure a clinical or biological
outcome. Such a study would employ transparent enroll-
ment, including only those who know their mutation
status or are willing to learn it in the setting of a trial.
Prior studies suggest that less than 10 % of all persons at
risk for carrying mutations for ADAD, however, may wish
to learn their genetic status [18], creating ethical and logis-
tical challenges to studies enrolling only mutation carriers.
Alternatively, trial designs employing blinded enrollment
do not require learning genetic status; for example,
enrolling all persons at risk for carrying mutations and
nonrandomly assigning noncarriers to placebo. These
trials may have higher rates of participation but will be
larger, more expensive, and carry unique ethical chal-
lenges. For example, side effects of investigational treat-
ments might inadvertently lead to unblinding of genetic
status for participants that do not wish to know it [17].
The Dominantly Inherited Alzheimer’s Network (DIAN)
is a multisite consortium study of ADAD. This longitu-
dinal study enrolls all persons at risk for harboring genetic
mutations that result in ADAD. Although the study does
not require participants to learn their genetic status,
genetic counseling, clinical genetic testing, and disclos-
ure of testing results are offered to all participants at no
charge to them. A primary objective of the DIAN is
to facilitate clinical trials of promising investigational
drugs for ADAD [16]. To assist in designing ADAD
clinical trials, a survey was developed to explore the
attitudes of DIAN participants toward trials and genetic
testing in the setting of these studies. In this paper, we
describe the results of this survey and the implications
for future clinical trials in ADAD.
Methods
Participants
Only participants enrolled in the DIAN were eligible to
participate in this survey study. The DIAN is a multisite
network that collects clinical, cognitive, imaging, and
biochemical assessments from members of pedigrees
with known pathogenic mutations in the PSEN1, PSEN2,
or APP genes [4, 19]. At the time of survey dissemin-
ation, the DIAN included 162 participants. Since then,
enrollment has surpassed 400.Survey
The data collection instrument was released to DIAN
sites as part of a protocol amendment to the larger
DIAN study on 28 March 2011. The survey included a
brief introductory letter that described the lack of
current therapies capable of preventing or slowing AD
and the great interest in developing such therapies. The
survey was described as providing feedback to investiga-
tors to facilitate the design of clinical trials in persons at
risk for ADAD. Participants were instructed to complete
the survey online (using an included website, username,
and password) or via an included hard copy. Survey
responses were anonymous; they were not linked to
any identifier for the DIAN study. Participants were
instructed to use caution to avoid using their name,
address, or any other personal identifying information
when completing and returning the survey.
Figure 1 illustrates the flow of the survey questions,
based on participant responses. The first survey item
was a multiple-choice question that inquired whether
the participant: (1) knew their genetic status, (2) did not
know their genetic status but wished to know, or (3) did
not know and preferred not to know their genetic status
at the present time. Participants who knew or wished to
know their genetic status were instructed to answer
Question A1, “Would you be interested in participating
in a research study of an experimental drug to determine
if that drug does (or does not) prevent or slow the
development of familial Alzheimer’s disease?” Response
choices for this question included “yes” or “no.” If the
participant answered “no” they were given the following
options and instructed to check all that apply: “I do not
carry the mutation that causes the disease in my family,”
“I would not want to risk the possibility of side effects,”
and “I would not want to spend the extra time and
effort.” Additionally, an “other” choice was offered, for
which participants could write in responses. Participants
answering yes to Question A1 were instructed to answer
three additional questions. Question A2 asked “Would
your opinion about such studies change if, instead of
knowing for sure that you would receive the real drug,
you had a 50 % chance of getting the real drug and a
50 % chance of getting a placebo (inactive drug or “sugar
pill”)?” (1:1 drug-to-placebo ratio). Question A3 asked
“Would your opinion about such studies change if,
instead of knowing for sure that you would receive the
real drug, you had two chances of receiving the real drug
and one chance of receiving placebo (that is, 2/3 of sub-
jects receive the real drug and 1/3 receive a placebo)”
(hereafter a 2:1 drug-to-placebo ratio). For both ques-
tions, the response choices were: (1) “I would be just as
interested,” (2) “I would be less interested,” and (3) “I
would be more interested.” Question A4 asked whether
“the possibility of receiving active drug after the study
Fig. 1 Survey flow diagram illustrating the order of survey questions. Based on their responses, participants were instructed to proceed to specific
sections of the survey (e.g., participants that did not wish to know their mutation status were instructed to complete only Section B) or to stop.
AD Alzheimer’s disease
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and offered (1) “I would now be interested” and (2) “I
would still not be interested” as responses.
Participants not interested in genetic testing were
instructed to complete Section B. Question B1 asked “If
you have chosen not to know your genetic status, would
you change your mind if learning that you carried the gene
mutation that causes familial Alzheimer’s disease gave you
the opportunity to participate in a research study of an
experimental drug attempting to prevent or slow thedevelopment of familial Alzheimer’s disease?” Participants
selecting “no” were asked to select all appropriate reasons
that applied: “I do not want to know if I will develop
Alzheimer’s disease,” “I do not want to participate in a
study of an unproven drug,” “I do not want to risk poten-
tial side effects of an unproven drug,” and “I do not want
to spend the extra time and effort.” An “other” choice was
offered with room for writing in responses. Questions B2,
B3, and B4 and their offered response choices were identi-
cal to those for Questions A2, A3, and A4.
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We examined the frequencies of responses within groups
based on the participants’ answer to the initial genetic
status question. Statistical comparisons were performed
after collapsing those who knew or wished to know their
mutation carrier status into a single group. This group
was compared with those who preferred not to know their
mutation carrier status. Frequencies of participant re-
sponses were compared between groups using chi-square
(χ2) tests. Inappropriate responses (e.g., participants who
responded that they knew their mutation status but
provided responses in Section B) were not included in the
statistical comparisons. In the event of missing data,
denominators were adjusted to compare proportions of
individuals responding to survey items.
Ethics
The DIAN longitudinal study is approved at each partici-
pating site by the local regulatory entity (i.e., institutional
review board (IRB) or ethics committee; see Acknowledge-
ments). All participants sign an approved informed con-
sent prior to engaging in any research activities. As part of
the DIAN protocol, the current survey was disseminated
across sites. For the purposes of the current study, the
University of California, Los Angeles, IRB deemed the
analysis of the anonymous survey results as not meeting
the definition of human subject research.
Results
Survey responses
Eighty participants completed the survey; 35 (44 %)
completed a paper version and 45 (56 %) completed the
survey online. Among participants, 32 (40 %) respondedTable 1 Frequencies of survey responses
Know/want to know
N 44 (55 %)
Interested in a clinical trial 38 (86 %)
50–50 drug-to-placebo randomization
Just as interested 21 (70 %)
Less interested 9 (30 %)
No longer interested 0 (0 %)
66–33 drug-to-placebo randomization
Just as interested 27 (90 %)
Less interested 2 (7 %)
No longer interested 1 (3 %)
Open-label extension study
Now be interested 29 (100 %)
Not be interested 0 (0 %)
Item responses are presented for those who know or wish to know their genetic m
the proportion of responses for the specific question). For “interested in a clinical tr
status if they would be willing to learn it to participate in a clinical trial
df degrees of freedomthat they knew whether they carried a gene mutation
that caused ADAD, 12 (15 %) did not know but wished
to learn their genetic status, and 36 (45 %) did not know
and preferred not to know their genetic status at the time
they completed the survey. There was no difference be-
tween those who completed the paper survey versus those
completing it online in the proportions that knew their
genetic status (χ2 = 0.67; degrees of freedom= 1, p = 0.71).
Table 1 presents the frequency of responses for those
who knew or wished to know their genetic status com-
pared with those who did not wish to know their genetic
status. We found no differences between the groups in
the frequencies of responses.
Attitudes of those who knew or wished to know their
genetic status
Among participants who knew or wished to know their
genetic status, 38 (86 %) were interested in participating
in a clinical trial. This included 81 % of participants who
knew their genetic status and 100 % of those who did
not know but wished to know their genetic status. Six
participants knew their genetic status but were not inter-
ested in participating in a clinical trial; four stated that
they did not carry the disease-causing mutation, one was
unwilling to risk side effects, and one was unwilling to
spend the extra time and effort.
Among those who knew or wished to know their
genetic status and were interested in clinical trials, 30
(79 %) responded to the items addressing the placebo
ratio. Seventy percent of those who responded were just
as interested in a trial with 1:1 randomization to drug or
placebo and 90 % were just as interested in a trial with
2:1 randomization. Four (20 %) participants who knewDo not want to know χ2, df, p value
36 (45 %)
26 (72 %) χ2 = 2.475, df = 1, p = 0.116
14 (58 %) χ2 = 1.75, df = 2, p = 0.416
9 (37 %)
1 (4 %)
15 (62 %) χ2 = 5.921, df = 2, p = 0.052
5 (21 %)
4 (16 %)
23 (96 %) χ2 = 1.232, df = 1, p = 0.267
1 (4 %)
utation status versus those who do not wish to know (percentages represent
ial,” the phrased question asked those who did not want to know their genetic
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placebo-controlled trial, compared with five (50 %) of
those who did not know their genetic status but wished
to (χ2 = 2.857, degrees of freedom = 1, p = 0.091). Only
one participant answered that they would not be inter-
ested in a placebo-controlled trial. This participant
knew their genetic status and stated they would refuse
a trial with a 2:1 drug-to-placebo ratio.
Each participant who answered whether the oppor-
tunity to participate in an open-label extension study
impacted their level of interest stated that they would be
interested (n = 29, 100 %).
Attitudes of those who did not want to know their
genetic status
Twenty-six (72 %) participants who preferred not to
learn their genetic status at the time of completing the
survey reported that they would change their mind if
learning that they carried a mutation gave them the
opportunity to participate in a clinical trial. The eight
participants who would not change their mind acknowl-
edged 11 responses why they would decline. Four did
not want to know if they would develop AD. Two did
not want to risk side effects of an unproven drug. Five
selected “other” and wrote in responses. Of these, two
said that they did not want to know their status at that
time and one stated they were too young to find out
their status; one stated that they had young children and
would not want to deal with side effects but that they
might be willing in future years; one did not want to risk
finding out their genetic status only to be placed on pla-
cebo; and one stated they would only want to know their
status if they knew more about the successes/failures of
the trials to this point.
Two participants who acknowledged interest in learn-
ing their genetic status and participating in clinical trials
did not answer the subsequent questions regarding
placebo. Nine of the 24 (37 %) participants who did not
want to know their genetic status but would be willing
to learn it in the setting of a clinical trial stated that they
would be less interested in a trial that had a 1:1 drug-to-
placebo randomization and one (4 %) stated that they
would no longer be interested. Five (21 %) participants
responded that they would be less interested in a trial
with 2:1 drug-to-placebo randomization and four (16 %)
stated they would no longer be interested. Twenty-three
(95 %) participants responded that they “now would be
interested” if there was the possibility of receiving active
drug after the study was completed.
Discussion
These results add to a literature describing the willing-
ness of persons at risk for ADAD to participate in
clinical research toward developing preventive therapies[17, 20]. Because of the survey’s anonymity and multisite
distribution, an exact response rate cannot be calculated.
A minimum response rate can be estimated, however,
given that at the time the last survey was received there
were 353 DIAN participants. Although the generalizability
of these results may be limited, some of the findings are
noteworthy. Among respondents, 80 % reported that they
would be willing to consider participating in a clinical trial,
even if it enrolled only persons harboring mutations
causing ADAD. Among those who knew or wished to
know their genetic status, 86 % endorsed interest in a
trial with unspecified design, but the proportion inter-
ested dropped when there was a possibility of a placebo.
The higher the chance of a placebo, the lower the inter-
est. Interest increased back to the level of the unspeci-
fied trial design if open-label extension was included as
part of the study. The findings suggest that, in contrast
to trials in sporadic AD [21], recruitment may be less of
a barrier to trial success in ADAD and support the
launch of the DIAN Trials Unit (DIAN-TU) [22].
The DIAN-TU was established to develop, initiate, and
coordinate clinical trials in the DIAN cohort [16]. The
first such trial, an adaptive-design phase II study of two
anti-amyloid-beta therapies with biomarker outcomes
that can transition into phase III efficacy measures, is
enrolling asymptomatic and very mildly symptomatic
persons at risk for ADAD [23]. The trial uses blinded
enrollment in which asymptomatic at-risk participants
are eligible to participate without the requirement of
genetic testing disclosure; noncarriers are nonrandomly
assigned to placebo. Mutation carriers are randomized
to active drug or placebo at a 3:1 ratio. Although it is
theoretically preferable to not mandate that persons
undergo genetic testing in order to participate in a pre-
vention study, there are challenges associated with this
approach. One potential issue is that mutation carriers
who do not know (and may not wish to know) their gen-
etic status might develop adverse effects from the active
drug. They would then be made aware of their genetic
status, with the potential for psychological reactions.
Another issue is the additional costs due to participation
of noncarriers, whose data do not contribute to determin-
ing whether an intervention is effective. It is therefore im-
portant that consideration be given to performing a study
enrolling only mutation carriers aware of their status.
In our survey, the frequency with which DIAN partici-
pants reported knowing (40 %) or desiring to learn their
genetic status (15 %) exceeds previous reports of clinical
and research testing for ADAD (often cited as less than
10 %) [17, 18] or other autosomal dominant neurode-
generative diseases (typically less than 25 %) [18, 24–26].
Several factors may contribute to this observation. The
DIAN offers free confidential genetic testing, which may
reduce barriers related to cost or concerns around
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bias associated with individuals who are willing to
participate in longitudinal clinical and biomarker assess-
ments also may account for differences from previous
reports of testing rates. Additionally, the initial papers
reporting rates of genetic testing in ADAD are now
more than a decade old [18]. The community of ADAD
families has therefore had time to learn about and
discuss genetic testing [18, 28] and an era of commercial
direct-to-consumer genetic testing has brought increased
public awareness and understanding of this technology,
potentially changing consumer or participant views [29,
30]. Further, since the DIAN was in part initiated with the
goal of conducting trials [16], enrollment may be skewed
toward individuals interested in therapeutic research and
those more likely to wish to learn their genetic status in
that setting. Finally, expectation for and the launch of the
DIAN-TU prevention trial in 2012 may have changed
family member views on genetic testing.
In fact, the majority (72 %) of participants who indi-
cated that they were not interested in learning their
genetic status responded that they were willing to do so
if it would allow them to participate in a clinical trial of
an experimental agent. Together with similar previous
results, [18, 20, 31], this finding suggests that trials
enrolling only persons who know or are willing to learn
their genetic status may be feasible. Such trials would
require smaller samples sizes than those of studies enrol-
ling all at-risk persons and would have substantially
reduced cost.
The decision whether to undergo predictive genetic
testing for ADAD is complex and highly individualized
[17, 25, 30]. Asymptomatic patients who choose to learn
their mutation status for autosomal dominant neurologic
disease may do so to reduce uncertainty and anxiety and
to inform life decisions [26, 32]. Although it will require
further study, several hypotheses emerge as to why the
opportunity to participate in a clinical trial may alter the
decision to learn genetic status for some participants.
First, it is unclear whether hypothetical responses pre-
dict actual behaviors. The proportion of participants in
this study who stated they would change their genetic
testing decision may or may not be inflated, compared
with what would happen in the setting of an actual
trial. Next, participants did not undergo systematic and
standardized education, counseling, or discussion with re-
searchers prior to completing the survey. The descriptions
of trials as testing potentially promising experimental
drugs (drugs that aim to slow or stop the progression of
AD) may therefore have influenced individuals to state
that they would be willing to learn their genetic status
despite previously indicating they did not wish to do so. In
the setting of fully informed consent (including essential
details such as the lack of guaranteed medical benefit andthe risk of learning mutation carrier status without such
benefit), it is possible that at least some of these individ-
uals would choose not to undergo genetic testing for the
sake of enrolling in a trial. Alternatively, the opportunity
to take action in the form of research participation may be
seen as a benefit of learning genetic status and may alter
the risk–benefit profile of the decision, where the risk
is learning that one harbors a disease-causing mutation.
Taking action, the hope associated with participation and
the knowledge that participants are contributing to scien-
tific advancement toward improved medical care for a
disease that they and their children may be destined to de-
velop are among the few benefits that investigators can
offer individuals at risk for ADAD. For some individuals,
these benefits may be enough to warrant learning genetic
status when they otherwise would not.
The ideal design for trials in populations at risk for
autosomal dominant neurological disorders remains de-
bated. Some investigators conclude that designs requir-
ing disclosure of genetic testing results are coercive [33].
The Belmont report defines coercion as using the threat
of harm to ensure compliance [34, 35]. Research partici-
pation is voluntary and rarely includes guaranteed health
benefits; the decision to decline participation is not
harmful. It should also be considered whether designs
requiring disclosure result in undue influence; offering
excessive or inappropriate reward to obtain compliance
[34, 35]. Trials should only test interventions with ad-
equate preclinical and early phase clinical results to
support their promise. Access to promising drugs may
represent an additional potential benefit for trial partici-
pants but is not an inappropriate reward for participa-
tion, even if access to therapy is guaranteed [36]. Both
ethical and practical issues can thus drive trial design
decisions [34]. For example, if inadequate numbers of
participants are willing to learn genetic testing results,
trials may need to employ blinded enrollment to be
feasible. These preliminary results suggest that this may
not be the case in ADAD, but future data will be needed
to clarify this issue. In all cases, investigators will need
to take precautions to ensure informed consent for tri-
als, to minimize risks related to either desired or un-
desired disclosure of testing results, and to monitor and
manage adverse effects of disclosure.
Limitations
The purpose of this survey was to provide anonymous
data to the leadership of the DIAN to assist in trial
design and planning. The lack of linked demographic
(race, ethnicity, education, geographic residence, etc.)
and other data (e.g., family age of onset of disease,
participant age relative to family age of onset) prevents
analyses for unique patterns or predictors of attitudes
toward clinical trials. The survey was not translated to
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speaking participants in the DIAN. Since participants
were all enrolled in the DIAN observational study, they
may not be representative of the greater population of
individuals at risk for ADAD, and even within the DIAN
we cannot rule out that a particular subset of partici-
pants with favorable attitudes toward clinical trials were
more likely to complete the survey. It is also possible
that those who completed the survey were early enrol-
lers in the DIAN, who may be most motivated to partici-
pate in research, including clinical trials. Although these
limitations may be minimized since the DIAN partici-
pants are likely to represent individuals willing to enroll
in ADAD trials, they may still result in an important
sample bias.
The survey was brief and instructed participants to
stop in the event that particular answers were given to
particular questions (see Fig. 1). Data were therefore not
collected regarding the willingness to participate in
clinical trials among those participants who did not
know or wish to know their genetic status and were not
willing to learn their genetic status in order to partici-
pate in a clinical trial. Ultimately, many of these partici-
pants are eligible for and may have enrolled in the
DIAN-TU, given that the design does not require learn-
ing genetic status. Furthermore, there are several aspects
of trial designs that impact willingness to participate,
such as risks of adverse events, which were not dis-
cussed in the survey. Importantly, adverse events related
to the drug under study could unblind mutation status
and adverse events related to study procedures are not
limited to those receiving therapy. Lastly, it is not clear
to what degree these survey responses predict actual
behaviors. Of note, however, at least 19 DIAN partici-
pants have chosen to undergo genetic testing since the
launch of the DIAN-TU.
Conclusions
The community of ADAD patients and families repre-
sents an increasingly informed population that includes
many individuals who are motivated to participate in re-
search and can be enrolled in clinical trials to examine
drug efficacy at well-defined clinical and pathophysio-
logical stages of disease. Clinical trials will be critical to
delaying and preventing the onset of cognitive impair-
ment and dementia in ADAD and may also be instruct-
ive toward research and treatment in sporadic AD. This
study confirms the strong desire of persons at risk for
ADAD to participate in clinical research to develop
therapies and suggests that such a desire may affect their
decision-making process toward learning genetic status.
Some persons who have a stated desire to not learn their
genetic status may change their minds in the setting of
a clinical trial and essentially all potential participantswould be willing to participate if the study offered an
open-label extension. The DIAN-TU will provide real-
world data on the rate at which persons not previously
undergoing testing will change their mind in the context
of a clinical trial, and our results suggest that consi-
deration can be given to performing preventive studies
enrolling only persons willing to undergo revealing
genetic testing prior to enrollment.
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